Anlon Healthcare IPO GMP Grey Market Premium
Anlon Healthcare IPO GMP is closed at ₹5 on 3 Sept 2025, estimating a profit of +5.49%. The IPO was oversubscribed 7.12x times, reflecting a strong demand of its shares over investors. Shares of Anlon Healthcare IPO are listed on both BSE and NSE exchanges on 3 Sept 2025 successfully. The highest grey market premium of Anlon Healthcare IPO was ₹5, estimating +5.49% profit. the lowest GMP was ₹0 on 24 Aug 2025.
| Lowest GMP | Present GMP | Highest GMP | Listing Gains |
|---|---|---|---|
| ₹0 | ₹5 | ₹5 | ₹1 |
| +0% | +5.49% | +5.49% | +1.1% |
Anlon Healthcare IPO is a Bookbuilding IPO, issuing 1.33 cr shares worth up to ₹121.03 Cr. On NSE, shares of Anlon Healthcare IPO are listed at ₹92, giving a profit of +1.1% over the IPO issue price of ₹91. On BSE, the same IPO shares are listed at issue price itself ₹91, resulting a flat listing. As per the last available GMP data, Anlon Healthcare IPO GMP is ₹5, which is not the actual listing premium. Hence the iporeturns.com Anlon Healthcare IPO GMP accuracy is 52.6%
Anlon Healthcare IPO GMP Live Tracker
The following table consists of live updates of Anlon Healthcare IPO GMP of last 10 days from the grey market. Investors can check the GMP trends of the IPO shares to understand its demand and decide whether to invest in the Anlon Healthcare IPO or to avoid it.
| GMP Date | GMP [₹91] | Sub2 Sauda Rate | Est. Profit | Est. Listing Price | IPO Event |
|---|---|---|---|---|---|
| 3-Sept | ₹5 | ₹600/8500 | 5.49% | ₹96 | Listed |
| 2-Sept | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 1-Sept | ₹5 | ₹600/8500 | 5.49% | ₹96 | Allotment |
| 31-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 30-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 29-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 28-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 27-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 26-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 25-Aug | ₹5 | ₹600/8500 | 5.49% | ₹96 | |
| 24-Aug | ₹0 | – | 0.00% | ₹91 | |
| 23-Aug | ₹0 | – | 0.00% | ₹91 |
The information on iporeturns.com regarding Anlon Healthcare IPO is for educational purposes only and does not constitute investment advice or guarantee returns. Investing in IPOs, including Grey Market Premium (GMP) data, carries significant risk, and past performance is not indicative of future results. Users are solely responsible for their investment decisions. iporeturns.com and its owners disclaim all liability for any losses.
What is Anlon Healthcare IPO GMP or Grey Market Premium?
Anlon Healthcare IPO Grey Market Premium is the premium price paid by investors in grey market for each Anlon Healthcare IPO share. The GMP price is the price at which an IPO share is traded in an unregulated and unofficial grey market just before listing of its shares. The grey market premium of Anlon Healthcare IPO reflects its demand factor among the investor community. If the GMP is positive, it signals a profitable listing on its listing date. If the GMP is low or negative, then it is expected to be listed at loss or discount and may be avoided by investors
In Anlon Healthcare IPO case, the latest available ₹5 over its issue price of ₹91. It is anticipated that, Anlon Healthcare IPO shares are expected to list at a premium of +5.49% Profit. However, on listing day, shares of Anlon Healthcare are listed at lower price of ₹92 only. Hence the Anlon Healthcare IPO GMP prediction is valid and accuracy is 52.6%.
However it should be noted that the Anlon Healthcare IPO GMP could be highly volatile and risky. Therefore, before to investing, please consider all factors of the Anlon Healthcare IPO and make correct decision before investing in it.
Anlon Healthcare IPO GMP Accuracy: 52.6%
The following table gives complete overview of grey market premium accuracy in terms of Direction Prediction, Return Magnitude and Price Estimation. As per the metrics, the iporeturns GMP accuracy of Anlon Healthcare IPO is 85%.
| Accuracy Component | Result | Score | Details |
|---|---|---|---|
| Direction Prediction | Correct | 100% | Predicted gain, got positive listing (+1.1%) |
| Return Magnitude | Overestimated | 20% | Predicted +5.49% but actual was +1.1% |
| Price Estimation | Poor | 95.3% | ₹96 vs ₹91.5 (₹4.5 overestimate) |
| iporeturns GMP Accuracy | Fair Performance | 52.6% | Correctly predicted direction but significantly overestimated magnitude |
Anlon Healthcare IPO Important Dates
| IPO Event | Date |
|---|---|
| IPO Open Date | 26-Aug-2025 |
| IPO Close Date | 29-Aug-2025 |
| Allotment Date | 1-Sept-2025 |
| Refund Date | 2-Sept-2025 |
| Credit to DEMAT | 2-Sept-2025 |
| IPO Listing Date | 3-Sept-2025 |
Disclaimer: The information provided about Anlon Healthcare IPO and its grey market premium (₹10) is for educational and informational purposes only. It should not be considered financial advice or a recommendation to invest. Please consult a qualified financial advisor before making any investment decisions. Investing in the Anlon Healthcare IPO or stock market, including IPOs, carries risks, and readers act at their own risk.
About Anlon Healthcare Limited Company
Anlon Healthcare Limited is a research-driven pharmaceutical company based in Rajkot, Gujarat, India. Established in 2013, the company specializes in the manufacturing of active pharmaceutical ingredients (APIs) and pharmaceutical intermediates used across human health, animal health, nutraceuticals, and personal care industries. With a strong focus on innovation and quality, Anlon Healthcare complies with global pharmacopeia standards including IP, BP, EP, JP, and USP, and exports to regulated markets such as Brazil, China, and Japan. The company operates a modern manufacturing facility near Gondal, Rajkot, equipped to handle commercial-scale production as well as custom manufacturing projects.
In August 2025, Anlon Healthcare launched its Initial Public Offering (IPO) worth ₹121.03 crore, with shares priced in the range of ₹86–₹91, aiming to strengthen its manufacturing capacity, repay debts, and fund working capital. Financially, the company has shown strong growth, with revenues crossing ₹120 crore in FY 2025 and profit after tax rising to over ₹20 crore, reflecting its expanding operations and growing market presence. Anlon Healthcare is recognized as one of the few Indian companies producing certain niche products, such as Loxoprofen Sodium Dihydrate, highlighting its competitive advantage.
With its increasing global reach, strong R&D capabilities, and commitment to regulatory compliance, Anlon Healthcare Limited is emerging as a reliable name in the pharmaceutical sector, well-positioned to benefit from the rising global demand for APIs and intermediates.
Anlon Healthcare IPO GMP Grey Market Premium FAQs
-
What is Anlon Healthcare IPO Grey Market Premium Today?
The last updated Anlon Healthcare IPO Grey Market Premium was ₹5, indicating an estimated +5.49% listing gain.
-
What is highest and lowest Anlon Healthcare IPO GMP rates?
Highest GMP: ₹5 (expected +5.49% profit)
Lowest GMP: ₹0 -
What is Anlon Healthcare IPO estimated listing price?
Based on the last GMP of ₹5 and issue price of ₹91, the expected listing price was around ₹96, estimating a profit of +5.49%.
-
What was the actual listing price of Anlon Healthcare IPO?
On NSE, shares of Anlon Healthcare IPO are listed at ₹92, giving a profit of +1.1% over the IPO issue price of ₹91. On BSE, the same IPO shares are listed at issue price itself ₹91, resulting a flat listing.
-
How accurate was the Anlon Healthcare IPO GMP prediction?
The GMP prediction had an accuracy score of 52.6%, as correctly predicted direction but significantly overestimated magnitude. Predicted +5.49% but actual was +1.1%.
-
What is the Anlon Healthcare IPO Subscription rate?
Anlon Healthcare is oversubscribed 7.12x times, showing strong investor demand.